NOVOB80 Stock Price and Chart — SET:NOVOB80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk faces class action lawsuits over alleged securities fraud linked to misleading dosing claims in the REDEFINE-1 trial, causing a stock drop to $85.00 per share.

Gerresheimer lowered its 2025 revenue forecast, potentially impacting Novo Nordisk's Wegovy injection pen production. The new growth rate is 3% to 5%, down from 7% to 10%.

Concerns arise over claims for GLP-1 drugs like Novo Nordisk's Ozempic, used off-label for obesity, sparking discussions on possible overmedication in the U.S.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.